INBX - Conference and earnings call announcements

– Event to be webcast live on Tuesday, September 8 th at 5:00 a.m. PT –SAN DIEGO, Sept. 4, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates, today announced that it will host a live webcast presentation on Tuesday, September 8, 2026 at 5:00 a.m. Pacific Time, to provide primary endpoint results from the randomized and controlled Phase 2 portion of the HexAgon study, which is evaluating the safety and efficacy of INBRX-106, a hexavalent OX40 agonist, in combination with pembrolizumab (the combination arm) versus pembrolizumab mono

– Event to be webcast live on Monday, May 11, 2026, at 5:30 a.m. PT –SAN DIEGO, May 8, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced that it will host a live webcast presentation on Monday, May 11, 2026 at 5:30 a.m. Pacific Time to provide interim results from the randomized, first-line Phase 2 portion of the HexAgon study, which is evaluating the safety and efficacy of INBRX-106, a hexavalent OX40 agonist, in combination with pembrolizumab (the combination arm) versus pembrolizumab monotherapy (the control arm) in first-li

SAN DIEGO, Nov. 18, 2022 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today announced it will be presenting at the following upcoming virtual investor conference: The Evercore ISI 5th Annual HealthCONx ConferenceWednesday, November 30th at 8:45 a.m. Pacific Time The investor conference presentation will be webcast live for at least 60 days following the event and will be accessible through a link on the investors section of Inhibrx's website at https://inhibr

– Event to be webcast live on Tuesday, October 4, 2022 at 5:30 a.m. PT – SAN DIEGO, Oct. 3, 2022 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced today that it will host a live webcast presentation on Tuesday, October 4, 2022 at 5:30 a.m. PT to announce the regulatory pathway for INBRX-101 for the treatment of patients with alpha-1 antitrypsin deficiency, or AATD. Investors may join via the web: https://app.webinar.net/8GArp0rQd3z or may listen to the c

Event to be webcast live on Monday, May 16, 2022 at 1:30 p.m. PT SAN DIEGO , May 12, 2022 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, today announced that it will host a live webcast presentation on Monday, May 16, 2022 at 1:30 p.m. PT to provide topline results from a Phase 1 clinical trial evaluating the safety and pharmacokinetics of INBRX-101 in patients with alpha-1 antitrypsin deficiency, or AATD. Investors may join via the web: https://app.webinar.net/60dmpLaBwqx o

SAN DIEGO, Nov. 1, 2021 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, announced today that the Company will be presenting at the Connective Tissue Oncology Society, or CTOS, 2021 Virtual Annual Meeting taking place November 10-13, 2021. CTOS Virtual Presentation Details: Title: Safety and Efficacy of the Tetravalent Death Receptor 5 Agonist INBRX-109 in Patients with Conventional Chondrosarcoma: Update from the Phase 1 Expansion CohortLead Author: Vivek Subbiah, MDAbstract:

SAN DIEGO, Sept. 13, 2021 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, announced today that the Company will be presenting at the following upcoming virtual investor conference: 2021 Cantor Virtual Global Healthcare Conference; Wednesday, September 29th, at 8:40 a.m. Pacific TimeThe investor conference presentation will be webcast live and may be accessed through a link on the investors section of Inhibrx's website at https://inhibrx.investorroom.com/events-a

SAN DIEGO, May 17, 2021 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, announced today that the Company will be presenting at the following upcoming virtual investor conferences: Jefferies Healthcare Conference; Wednesday, June 2nd at 12:30 p.m. Pacific Time JMP Securities Life Sciences Conference; Thursday, June 17th at 8:00 a.m. Pacific TimeThe investor conference presentations will be webcast live and may be accessed through a link on the investors section o

SAN DIEGO, Feb. 1, 2021 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, announced today that the Company will be presenting at the following upcoming virtual investor conference: Guggenheim Healthcare Talks: 2021 Oncology Days; Friday, February 12th, at 2 p.m. Pacific Time The investor conference presentation will be webcast live and may be accessed through a link on the investors section of Inhibrx's website at https://inhibrx.investorroom.com/events-and-presentations. The webcast will be available for 60 days following the event. About Inhibrx, Inc. Inhibrx is a clinic